Pure Global
NCT06415682

The Efficacy and Mechanism of SMA+M1 Repetitive Transcranial Magnetic Stimulation on Freezing of Gait in PD

The First Affiliated Hospital with Nanjing Medical University·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
Transcranial Magnetic Stimulation
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
The First Affiliated Hospital with Nanjing Medical University
Timeline & enrollment
Phase
N/A
Start date
May 06, 2024
End date
Dec 06, 2024
Enrollment
53 participants
Primary outcome

Changes of Freezing of Gait severity

Summary

This study is a double-blinded randomized study examining the efficacy of the double-site
 (M1+SMA) repetitive transcranial magnetic stimulation on Freezing of Gait (FOG) in patients
 with Parkinson's disease. The investigators hypothesize that treatment using magnetic
 stimulation on double site (including M1-LL and SMA) will improve FOG and gait symptoms in
 patients with Parkinson's disease.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06415682
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06415682 through Pure Global AI's free database. This phase not specified trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 53 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.